LeMaitre initiated with a Hold at Freedom Capital

Freedom Capital initiated coverage of LeMaitre (LMAT) with a Hold rating and $113 price target The peripheral vascular surgery focused medtech company has leadership positions in niche markets across five key product categories, notes the analyst, whose neutral outlook is driven primarily by a belief that annual realized price increases are likely to moderate in out-years.